Neoadjuvant Chemotherapy Therapy News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

European Commission approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
Basel, 23 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Phesgo®, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection for the treatment of early and metastatic HER2-positive breast cancer.“This approval represents a significant step forward in the treatment of HER2-positive breast cancer,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “The innovation of Phesgo significantly reduces the ti...
Source: Roche Media News - December 23, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
Basel, 23 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Phesgo®, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection for the treatment of early and metastatic HER2-positive breast cancer.“This approval represents a significant step forward in the treatment of HER2-positive breast cancer,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “The innovation of Phesgo significantly reduces the ti...
Source: Roche Investor Update - December 23, 2020 Category: Pharmaceuticals Source Type: news

Immediate Breast Reconstruction Feasible Following Neoadjuvant Chemo Immediate Breast Reconstruction Feasible Following Neoadjuvant Chemo
Long-term oncologic outcomes following neoadjuvant chemotherapy for breast cancer are similar with immediate breast reconstruction and conventional mastectomy alone, regardless of response to chemo, according to a retrospective study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 27, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

' Watch and Wait' Feasible for Some Rectal Cancer Patients
TUESDAY, Nov. 3, 2020 -- A " watch-and-wait " (WW) strategy may be an option for carefully selected patients who achieve a complete response (CR) to neoadjuvant chemoradiation (nCRT) for rectal adenocarcinoma, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 3, 2020 Category: Pharmaceuticals Source Type: news

Oncotarget: quantitative ultrasound radiomics in prediction of treatment response for breast cancer
(Impact Journals LLC) The cover for Issue 42 ofOncotarget features Figure 4, " Generation of parametric and texture maps from radiofrequency data, " recently published in " Quantitative ultrasound radiomics using texture derivatives in prediction of treatment response to neo-adjuvant chemotherapy for locally advanced breast cancer " by Dasgupta, et al. which reported that to investigate quantitative ultrasound based higher-order texture derivatives in predicting the response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 21, 2020 Category: International Medicine & Public Health Source Type: news

Image-Guided Biopsy May Help Some Avoid Breast Cancer Surgery Image-Guided Biopsy May Help Some Avoid Breast Cancer Surgery
Following neoadjuvant chemotherapy, image-guided vacuum-assisted biopsy (VAB) can reliably identify a subgroup of patients with no residual disease in the breast, according to an analysis of pooled data drawn from three continents.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - October 20, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Dual checkpoint blockade promising as pre-surgical approach for certain patients with localized bladder cancer
(University of Texas M. D. Anderson Cancer Center) Phase I trial finds neoadjuvant combination checkpoint inhibitors (anti-CTLA-4 plus anti-PD-1) was well tolerated and showed early signs of activity in certain patients with bladder cancer. These patients cannot be treated with chemotherapy and have no standard treatment options available. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 12, 2020 Category: Cancer & Oncology Source Type: news

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
Basel, 19 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq ® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.“While we have made great progress in the treatment of many forms of breast cancer, TNBC remains an aggressive and difficult-to-treat disease,” said Levi Garraway, M.D., Ph.D., Roche ' s Chief Medical Officer and Head of Global Product Development. “We are proud of our work to address challenges a...
Source: Roche Media News - September 19, 2020 Category: Pharmaceuticals Source Type: news

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
Basel, 19 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq ® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.“While we have made great progress in the treatment of many forms of breast cancer, TNBC remains an aggressive and difficult-to-treat disease,” said Levi Garraway, M.D., Ph.D., Roche ' s Chief Medical Officer and Head of Global Product Development. “We are proud of our work to address challenges a...
Source: Roche Investor Update - September 19, 2020 Category: Pharmaceuticals Source Type: news

Neoadjuvant Chemoradiotherapy Best Restricted to High-Risk Rectal Cancer Patients Neoadjuvant Chemoradiotherapy Best Restricted to High-Risk Rectal Cancer Patients
Because neoadjuvant chemoradiotherapy in patients with rectal cancer carries a high risk of adverse effects, careful selection is needed to avoid possibly harmful treatment, according to new research.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - August 3, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Pathological regression of lymph nodes better predicts esophageal cancer survival
(Osaka University) A team of researchers led by Osaka University established a new pathological grading system to evaluate the therapeutic effect of neoadjuvant chemotherapy (NAC) for metastatic lymph nodes (LNs) removed in esophageal cancer (EC) surgery, demonstrating that the system predicts recurrence and prognosis in EC patients better than conventional systems. Their findings will enable 'tailor-made' treatment according to the pathological assessment of all metastatic LNs, eventually improving treatment performance of EC. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 27, 2020 Category: International Medicine & Public Health Source Type: news

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers and is difficul...
Source: Roche Investor Update - July 13, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers and is difficul...
Source: Roche Media News - July 13, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer
Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Phesgo ™, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC injection.“The FDA approval of Phesgo reflects our commitment...
Source: Roche Media News - June 29, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer
Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Phesgo ™, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC injection.“The FDA approval of Phesgo reflects our commitment...
Source: Roche Investor Update - June 29, 2020 Category: Pharmaceuticals Source Type: news